AMD – a glimpse into the futureJaheed Khan
Symptoms of AMD
Dry AMD
Wet AMD
Wet AMD scarring
Dry AMD OCT
OCT wet AMD
Treatments for Dry AMD
No medical treatment for dry type
Magnifying vision and good illumination help
IMT for end stage AMD
Focal laser for wet AMD
Photodynamic therapy
RPE Cell Translocation
VEGF
Anti –VEGF Rx
Anti-VEGF differences
Radiotherapy Rx for wet AMD
Future AMD Rx
Future AMD Rx
Future AMD Rx
Future AMD Rx
Future AMD Rx
Future AMD Rx
Future AMD RxDry AMD pipeline: most promising candidates
• Ciliary Neurotrophic Factor: Neuroprotective implant, phase II• Fenretinide: Decreases serum retinol, oral, phase II• OT-551: Anti-oxidant, anti inflammatory, topical, phase II• POT-4: Complement C3 inhibitor, phase II• Glatiramer Acetate: Immunomodulator, subcutaneous, phase II• Rheopheresis: Plasmapheresis, phase III
Future AMD RxWet AMD pipeline: most promising candidates • adPEDF.11: Gene therapy, intravitreal injection, phase I• AGN211745: siRNA, intravitreal injection, phase II• Zybrestat: vascular disrupting agent, topical, animal studies• Sirolimus: Multi-mechanism, Subconjunctival or intravitreal injection or oral, phase II• ATG003: nAChR antagonist, topical , phase II• Vatalanib: Tyrosine kinase inhibitor, oral, phase II• Pazopanib: Tyrosine kinase inhibitor, , topical , phase II• TG101095 / TG100801: Tyrosine kinase inhibitor, topical, phase II• AL-39324: Tyrosine kinase inhibitor, intravitreal injection, animal studies• AG013958: Tyrosine kinase inhibitor, subtenon injection, animal studies• JSM6427: integrin antagonist, intravitreal injection, phase I• PF-04523655 (REDD14NP) Wet AMD; phase I (Quark/Pfizer)
AMD – a glimpse into the future